BioMarker Strategies Awarded Fast-Track SBIR Contract from National Cancer Institute to Develop SnapPath System

BALTIMORE--(BUSINESS WIRE)--BioMarker Strategies, LLC announced today that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) contract from the National Cancer Institute to develop the SnapPath™ live-tumor-cell testing system. BioMarker Strategies is developing the SnapPath™ system to enable oncologists to determine the most effective drug treatment for their cancer patients. Under this contract, the company will receive an initial award of $254,000 and be eligible to receive an additional $2 million when the first phase of work is completed—for a total potential contract amount of $2.3 million.